MedTrace Logo

Acamprosate Safe to Use in Individuals With Liver Disease.

NCT04287920 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-12-20

Study results available
· View outcomes & findings →

Summary

Is acamprosate safe to use in individuals with liver disease.

Conditions

  • Alcohol-related Liver Disease

Interventions

DRUG

Acomprosate

Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months

Sponsors & Collaborators

Principal Investigators

  • Douglas A Simonetto · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2022-01-05
Completion
2022-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04287920 on ClinicalTrials.gov